Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Braze Inc (BRZE) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

Recursion Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Braze Inc vs Recursion Pharmaceuticals Inc — how do they compare? Braze Inc trades at $27.6 (market cap $3.18B), while Recursion Pharmaceuticals Inc trades at $3.29 (market cap $1.81B). The key difference: Braze Inc is the larger of the two by market cap, and Braze Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

BRZERXRX
Market Cap
$3.18B$1.81B
Sector
TechnologyHealth
52-Week High
$36.19$6.79
52-Week Low
$15.79$2.84
Enterprise Value
$2.87B$1.33B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Braze Inc

Braze (BRZE) trades at $27.50, down 4.35% today but showing strong technical momentum with bullish moving averages. The company demonstrates impressive revenue growth, reaching $593.41 million in 2025 with 30% year-over-year expansion, though profitability remains elusive with a -15.51% net margin. Recent news highlights insider selling but also strong AI-driven customer engagement demand and four consecutive quarters of organic revenue acceleration.

The outlook remains positive with 96% analyst buy ratings and a $34.78 consensus target suggesting 26% upside. Key risks include persistent unprofitability despite growth and competitive pressures in the customer engagement software space. The stock's trajectory depends on continued revenue acceleration and eventual path to profitability.

Recursion Pharmaceuticals Inc

RXRX trades at $3.295, up 0.15% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a Q2 2026 earnings miss with revenue declining year-over-year, while maintaining a strong cash position from financing activities. Recent news highlights participation in investor conferences and partnership advancements with Genentech.

Outlook remains speculative with high revenue growth potential from AI-driven drug discovery partnerships, but significant risks persist due to deep losses and negative margins. Analyst sentiment is mixed with a 40% buy rating, emphasizing the stock's high-risk, high-reward profile dependent on future clinical and commercial milestones.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Braze Inc

Braze Inc is a customer engagement platform that powers customer-centric interactions between consumers and brands. The company provides solutions for Retail & E-commerce, Media & Entertainment, Financial Services, and Travel & Hospitality related industries.

Read more on BRZE

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.

Read more on RXRX